Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Exon 7 Deletion in the bcr-abl Gene Is Frequent in Chronic Myeloid Leukemia Patients and Is Not Correlated with Resistance against Imatinib

Gaillard, Jean-Baptiste, Arnould, Cécile, Bravo, Sophie, Donadio, Daniel, Exbrayat, Carole, Jourdan, Eric, Reboul, Dorothée, Chiesa, Jean, Lavabre-Bertrand, Thierry · 2010 · Molecular Cancer Therapeutics

Abstract

Chronic myeloid leukemia (CML) patients treated with imatinib develop frequent resistance generally due to a point mutation. Recently, large rearrangements of abl sequence have also been described. In this study, we focused on the complete deletion of exon 7. We screened for bcr-abldelexon7 in 63 resistant patients by high-resolution melting (HRM) analysis and direct sequencing. Moreover, we analyzed expression of abldelexon7 and bcr-abldelexon7 in 17 CML patients at diagnosis, 32 patients at resistance, and 20 negative controls by quantitative PCR or fragment length analysis. bcr-abldelexon7 was detected on 34 (54%) among 63 resistant patients by HRM, showing an increase in the sensitivity of screening, because only 3.2% could be detected by direct sequencing. This deletion was not associated with a point mutation (P = 0.3362). In addition, abldelexon7 was found in all tested samples with the same pattern of expression, suggesting an alternative splicing mechanism. In the bcr-abl component, there was no statistical difference between CML patients at diagnosis and resistant patients (P = 0.2815) as regarding bcr-abldelexon7 proportion, thus arguing against involvement of deletion in resistance. Moreover, among two patients harboring bcr-abldelexon7 at diagnosis, one experienced a complete disappearance of this transcript, and the other decreased >75% at resistance. In conclusion, bcr-abldelexon7 is frequently observed in CML patients when using sensitive techniques. It seems to be the result of an alternative splicing mechanism and to be independent from the occurrence of resistance. Mol Cancer Ther; 9(11); 3083–9. ©2010 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-10-0595

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Cited by

See all 23

Metadata

Authors
Gaillard, J.-B., Arnould, C., Bravo, S., Donadio, D., Exbrayat, C., Jourdan, E., Reboul, D., Chiesa, J., & Lavabre-Bertrand, T.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Authors' Affiliations: Departments of 1Clinical Cytology and Cytogenetics and 2Hematology, Nîmes University Hospital, Nîmes, France; 3UMR-CNRS 5247, Montpellier, France; and 4Hématologie et oncologie médicale, Clinique du Parc, Castelnau Le Lez, France
Venue
Molecular Cancer Therapeutics
Published
2010-11-01
Volume
9
Issue
11
Pages
3083-3089
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2151186464
Cited by
23
References
35
Citations by year
2026: 1 · 2024: 1 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 3 · 2015: 2 · 2014: 1 · 2013: 1
FWCI
1.40
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Cancer Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
chronic myeloid leukemia, BCR-ABL, exon 7 deletion, imatinib resistance, alternative splicing, point mutations, high-resolution melting analysis, transcript expression
MeSH terms
Imatinib Mesylate, Antineoplastic Agents, Benzamides, DNA Mutational Analysis, Exons, Gene Frequency, Genetic Testing, Humans, Nucleic Acid Denaturation, Piperazines, Pyrimidines, Temperature, Cohort Studies, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Gene Deletion, Drug Resistance, Neoplasm, Protein Isoforms, Genetic Association Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exon 7 Deletion in the bcr-abl Gene Is Frequent in Chronic Myeloid Leukemia Patients and Is Not Correlated with Resistance against Imatinib. https://app.cochat.ai/papers/10.1158/1535-7163.mct-10-0595
The paper
Gaillard, J.-B., Arnould, C., Bravo, S., Donadio, D., Exbrayat, C., Jourdan, E., Reboul, D., Chiesa, J., & Lavabre-Bertrand, T. (2010). Exon 7 Deletion in the bcr-abl Gene Is Frequent in Chronic Myeloid Leukemia Patients and Is Not Correlated with Resistance against Imatinib. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-10-0595

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.